Executive Committee

Dr Roch Doliveux

Chief Executive Officer and Chairman of the Executive Committee 

Doctor in Veterinarian Medicine from Maisons-Alfort (France), Roch Doliveux is also Laureate of the Faculty of Medicine, Créteil, and holds an MBA from INSEAD (France) with distinction.

He joined the pharmaceutical industry early, first at Ciba-Geigy (now Novartis) in Switzerland, in Peru and in France, and then at Schering-Plough Corporation in various positions, including President of Schering-Plough International. Then, Roch Doliveux joined the Pierre Fabre group as Chief Executive Officer of Pierre Fabre Pharmaceuticals.

Roch Doliveux joined UCB in October 2003 as Director General of the Pharma Sector and Deputy Chairman of the Executive Committee. He became CEO and Chairman of the Executive Committee of UCB Group on January 1, 2005. He is a member of the Board of Directors of UCB, as well as a member of the Board of the European Federation of Pharmaceutical Association (EFPIA), of the INSEAD International Council, the Science & Business Innovation Board, the Caring Entrepreneurship Fund (King Baudouin Foundation) and WELBIO (Walloon Institute for Life Lead Sciences).

Detlef Thielgen

Executive Vice President and Chief Financial Officer

Appointed in January 2007. Previously CFO of Schwarz Pharma AG, Managing Director of Schwarz Pharma Operations covering the worldwide manufacturing and supply chain functions and Vice-President Finance & Administration/CFO at Schwarz Pharma Inc/USA.

Iris Löw-Friedrich

Executive Vice President, Development and Chief Medical Officer

Appointed in March 2008. Previously Head of R&D and member of the Executive Board of Schwarz Pharma AG, after having held the position of VP Global Projects at BASF Pharma. Since June 2007, she is also a member of the Supervisory Board of Wilex AG.

Fabrice Enderlin

Executive Vice President, Corporate Human Resources

Appointed in March 2008. Previously Vice President Human Resources at GSK Biologicals, and at GSK France, Novartis, and Arcelor/Mittal. Graduated from the "Political Sciences Institut" and has a master degree in HR.

Bob Trainor

Executive Vice President and General Counsel

Appointed in October 2004. Previously Vice President, Associate General Counsel of Schering-Plough; Assistant General Counsel of Johnson & Johnson; Attorney with the New York law firm Donovan Leisure Newton & Irvine and started as Counsel of the Committee on the Judiciary at the United States House of Representatives.

Mark McDade

Executive Vice President, Global Operations

Mark McDade joined UCB SA as Executive Vice President, Corporate Strategy and Business Development in April 2008. From 2002 until late 2007 he was Chief Executive Officer and a Director of PDL BioPharma, Inc. Prior to PDL, he served as CEO of Signature BioScience, Inc. and was previously a co-founder and director of Corixa Corporation, where he served as Chief Operating Officer from September 1994 through December 1998 and as President and Chief Operating Officer from January 1999 until his departure in late 2000. Before Corixa, Mark McDade was Chief Operating Officer of Boehringer Mannheim - Therapeutics, and prior to that held several positions at Sandoz Ltd. including business development, product management and general management. Mark McDade received a B.A. from Dartmouth College and an M.B.A. from Harvard Business School.

Michele Antonelli

Executive Vice President Technical Operations & Quality Assurance

Appointed in September 2007. Michele has a degree in Plant Biology from the University of Bari, Italy, and qualified the ENI's post graduate program in Biotechnology and in Advanced Genetics (molecular and somatic cell) at the Catholic University of Piacenza and the Iowa State University of Ames, USA.
From 1985 to 1992, he worked at Enichem, in Italy, as Research Fellow and then Head of the Molecular and Cell Biology Unit. In 1992 he joined Serono where he held several senior managerial positions until the present day, gathering about 15 years experience in the QA and Manufacturing fields. His last position there was as Senior Vice President Biotech Manufacturing & Process Development, based in Geneva.

Ismail Kola

Executive Vice President, UCB & President, New Medicines™

Appointed in November 2009.
Ismail holds a Ph.D. in Medicine from the University of Cape Town, South Africa.
He joined UCB from Schering Plough Corporation where he was Senior Vice President, Discovery Research and Early Clinical Research & Experimental Medicine, Schering-Plough Research Institute, the pharmaceutical research arm of Schering-Plough Corporation, and Chief Scientific Officer, Schering Plough Corporation. He was also responsible for Early Clinical Research and Experimental Medicine.
Ismail came to Schering-Plough from Merck, where he was Senior Vice President and Site Head, Basic Research, and responsible for atherosclerosis and cardiovascular diseases, diabetes, obesity, infectious diseases, immunology and rheumatology, animal pharmacology and basic and medicinal chemistry. He also chaired Merck's Antibacterial and Antifungal Worldwide Business Strategy Team. Prior to that, he was Vice President, Research, and Global Head, Genomics Science and Biotechnology, with Pharmacia Corporation, and served as a consultant to SmithKline Beecham Pharmaceuticals, where he was also a member of the Genomics Advisory Board.
He holds Adjunct Professorships of Medicine at Washington University, St Louis, Missouri, USA, and Monash University Medical School, Melbourne, Australia; a Foreign Adjunct Professorship at The Karolinska Institute, Stockholm, Sweden; and is a William Pitt Fellow at Pembroke College, Cambridge University, UK.